Table 2. Geometric mean titres and concentrations by treatment groups.
| Placebo | 3 × 105 pfu | 1 × 107 pfu‡ | 5 × 107 pfu‡ | ≥1 × 107 pfu | p value* | p value† | |
|---|---|---|---|---|---|---|---|
| EBOV-GP ELISA USAMRIID (GMT) | |||||||
| Day 0 | 25 | 26·0 (24·5–27·6) | 33·9 (26·6–43·4) | 36·3 (26·1–50·5) | 34·6 (28·4–42·1) | .. | .. |
| Day 28 | 25 | 344·5 (229·7–516·4) | 1064·2 (757·6–1495·1) | 1780·1 (1048·3–3022·5) | 1227·0 (917·3–1641·2) | <0·0001 | <0·0001 |
| EBOV-GP ELISA ADI (EU per mL) | |||||||
| Day 0 | 66·0 (56·5–77·2) | 69·6 (59·7–81·0) | 51·2 (42·2–62·0) | 63·1 (48·0–83·0) | 54·6 (46·6–64·0) | .. | .. |
| Day 28 | 60·0 (46·4–77·5) | 241·4 (173·8–335·4) | 342·3 (232·9–503·0) | 392·8 (237·2–650·5) | 355·6 (261·0–484·4) | 0·022 | 0·032 |
| Whole-virion ELISA (EU per mL) | |||||||
| Day 28 | 500 | 614·7 (524·3–720·5) | 982·9 (721·1–1339·6) | 1285·1 (738·9–2235·3) | 1058·6 (807·9–1387·1) | 0·0005 | 0·001 |
| PsVNA50 (GMT) | |||||||
| Day 0 | 10 | 10 | 10 | 10 | 10 | .. | .. |
| Day 28 | 10 | 35·4 (24·7–50·7) | 99·1 (61·9–158·9) | 231·8 (126·7–424·3) | 127·0 (86·0–187·6) | <0·0001 | <0·0001 |
Data are geometric endpoint titres (GMT) or mean concentrations (GMC) of ELISA units per mL with 95% CIs. pfu=plaque-forming units. EBOV-GP=Zaire Ebolavirus glycoprotein. USAMRIID=US Army Medical Research Institute of Infectious Diseases. ADI=Alpha Diagnostic International. EU=ELISA units. PsVNA50=pseudovirion neutralisation assay.
*
Cuzick’s test for three group comparisons of recipients of 3 × 105 pfu, 1 × 107 pfu, and 5 × 107 pfu.
†
Mann-Whitney test for two group comparisons of low-dose (3 × 105) and high-dose (≥ 1 × 107) vaccinees.
‡
Results from participants injected with 1 × 107 pfu and 5 × 107 pfu, previously reported,9 are provided for comparison.